Penumbra, Inc. (PEN) Earnings Call Transcript & Summary

August 4, 2022

New York Stock Exchange US Health Care Health Care Equipment and Supplies earnings 61 min

Earnings Call Speaker Segments

Jee Hamlyn-Harris

executive
#1

Operator, thank you, and I'm glad all of you could join us today as we review how Penumbra performed during the second quarter of 2022. Our press release is available, and so are the financial tables — which include a reconciliation between GAAP and non-GAAP figures — located under the Investors section of our website, www.penumbrainc.com. During this call, we will present forward-looking statements in accordance with the safe harbor protections established by the Private Securities Litigation Reform Act of 1995, addressing subjects such as our financial results, commercialization efforts, clinical trials, regulatory matters, quality, compliance, and business trends. What we actually report could end up looking quite different from anything these forward-looking statements describe or suggest. That's because of a number of risks and uncertainties, and you can find examples of them in the 10-K we filed with the SEC covering the year that closed on December 31, 2021. Given that, please don't lean too heavily on these forward-looking statements. We'd also suggest you go through the filings we make with the SEC on a periodic basis, that 10-K included, since they lay out in more detail these factors along with other risks capable of shaping our future results or what our stock trades for — among them, though not limited to, the way the COVID-19 pandemic bears on our business, our results of operations, and our financial conditions. Penumbra states that it has no obligation to refresh or amend its forward-looking statements, whether as a result of fresh information, later occurrences, future developments, or any other reason. During this call, certain financial metrics are reported using a non-GAAP approach. The matching GAAP figures, along with the reconciliation between GAAP and non-GAAP financial metrics, can be found in the press release we have posted. Business updates will come from Adam Elsesser, who serves as Penumbra's Chairman and CEO, together with Sandra Lesenfants, our President of Interventional. After that, Maggie Yuen, our Chief Financial Officer, will review the financial results we recorded for the second quarter. Our 2022 guidance will be covered by Jason Mills, our Executive Vice President of Strategy. Having said that, I'd now like to hand the call over to Adam Elsesser.

Adam Elsesser

executive
#2

Thanks, chief. Good afternoon, everyone, and thank you for being with us on Penumbra's call for the second quarter of 2022. Revenue overall came to $208.3 million in Q2, which represents a 13.1% rise versus the prior-year period as reported, and 15.3% on a constant currency basis. Within that, global vascular revenue was up 22.7%, while global neuro revenue rose 1.5% against the same quarter last year. Sequentially, gross margins improved by 180 basis points, reaching 64.3%. Non-GAAP operating income came in at $1.6 million, equal to 0.8% of revenue, for the second quarter. Looking forward, we expect revenue to rise during the second half of the year, with growth accelerating in 2023, powered by four key catalysts, three big product launches, and the release of important clinical data. Sandra will cover these catalysts shortly as well. Equally crucial given today's economic conditions, we see gross margins continuing to climb, targeting 70%+ within a few years. Despite the ongoing macroeconomic slump, we plan to build operating profitability through discipline and operational gains. I think these catalysts—spanning both neuro and vascular, plus what we're doing around gross margins and operating profitability—are going to make the coming 12 to 18 months one of the strongest stretches Penumbra has ever seen. Looking back at Q2, our team performed in a way that makes me proud, even with an extremely tough operating backdrop, mostly here in the United States. Year-over-year U.S. growth came in at 10.2%, which fell short of what we'd expected and below what we anticipate going forward. Over the last several months, the biggest obstacles across our sector were ongoing staffing shortages, which made workflow difficult for our hospital partners. On the topic of supply, we believe those problems have eased, though we're still keeping an eye on them in some parts of the world. Our team keeps tackling supply chain difficulties successfully and with determination, though it takes considerable work. These issues were clear before and remain so now, yet our ability to handle them is improving, and we anticipate reducing their effects even more in the back half of the year, when we expect faster growth in our U.S. operations. Internationally, we posted 20% growth compared with the same period a year earlier, and that segment is beginning to achieve scale. That said, currency rate movements hurt our second quarter performance, and we anticipate that FX will continue to drag on reported revenue throughout the latter portion of 2022. Jason is going to cover that point afterward during this call. With that being said, having both our domestic and overseas operations, along with the two major segments we compete in—neuro and vascular—provides us a wide-ranging product lineup and a global footprint that lets us thrive under almost any macroeconomic conditions. Now on to our vascular business. For the second quarter, we posted a 22.7% increase compared with the same period last year, reaching $123.5 million. Revenue from vascular thrombectomy rose 30.3% versus a year earlier, while vascular embolization revenue was up 11.8% year-over-year. Our U.S. The expansion we saw in vascular was mostly a result of greater use among current customers—those who already have faith in thrombectomy but had only begun to explore what our technology can do—rather than from stocking new accounts that mostly rely on Lytics. In fact, our internal review leads us to conclude that we came out ahead against competitors in both venous and arterial thrombectomy in Q2. Although certain macroeconomic forces I mentioned before evidently influenced how our U.S. vascular business grew in Q2, during the last month we've witnessed a robust rebound in the momentum behind our vascular thrombectomy operations. Our current offerings for arterial and venous conditions—Lightning 12 along with Lightning 7—represent a novel treatment strategy spanning those two vascular territories, and through them we've started eliminating the typical trade-offs that come with mechanical thrombectomy. Looking ahead, we believe our two forthcoming vascular products, Lightning Flash and Lightning Bolt, are going to lift us into an even higher level of technological leadership in both of those markets. Lightning Flash brings in a newly designed advanced catheter and adds a next-generation Lightning algorithm employing a highly innovative method for selectively regulating aspiration, which we anticipate will let us pull out more clot, cut the time required for the procedure even further, and better optimize mitigation of blood loss while lowering the danger of damage to the vessel lumen. While Lightning Flash may prove just as significant in the venous market, our enthusiasm for what Lightning Bolt could achieve in the arterial anatomy is just as great. An exceptionally refined algorithm forms the basis of Lightning Bolt's design. This technology brings together the dual pressure sensors already part of our existing Lightning algorithm, which assist in mitigating blood loss, and the clot extraction capability built into Thunderbolt for ischemic stroke, a topic I'll cover shortly. Beyond that, our team, working alongside key opinion leaders, is pushing forward substantial clinical efforts and assembling evidence that our proprietary breakthroughs enhance outcomes, lessen complications, and move the whole field ahead. We anticipate far more conversation about pivotal clinical work at upcoming medical meetings, since numerous physicians are gathering and sharing their experiences with our technology as compared with rival offerings. To give you an example, during the VTE Summit that took place in San Diego not long ago, independent findings were shared covering 85 individuals with DVT who had been treated with thrombectomy systems currently in use, Lightning 12 being one of them, and those outcomes came out comparatively better. We're keen for this data, together with other independent data sets, to be presented, published, and debated going forward. On top of that, we expect that the initial 60 patients enrolled in our STRIKE-PE trial will be presented at the PERT Symposium in October, which we believe will highlight our position in the PE market. Turning to the arterial side, we expect to complete enrollment in our STRIDE study before the year ends, with acute results anticipated for presentation next spring—which we think will boost awareness and uptake of Lightning 7 in acute limb ischemia; on top of that, Sandra will cover two new randomized clinical trials we intend to run in vascular thrombectomy in the near term. When it comes to coronary, CAT RX kept up a robust upward path across the U.S., and so did our vascular embolization unit, despite the fact that the macro conditions this quarter did affect the latter. On top of that, we kicked off a pair of successful European launches — Lightning 12 along with Lightning 7. Beyond that, rolling out our initial Indigo thrombectomy offerings in China went well, and we anticipate solid expansion ahead. We're additionally preparing to bring our vascular thrombectomy lineup to the Japanese market. Now shifting to neurovascular: revenue for the second quarter climbed to $84.8 million, which is a 1.5% rise versus the same period a year ago and 4.6% higher quarter over quarter. Our U.S. stroke segment once more posted robust double-digit year-over-year gains, though our neuro embolization arm and the international stroke operation counterbalanced that increase; we're thrilled to share that the FDA has approved our IDE for the THUNDER trial, which in effect ushers in the Thunderbolt period for stroke treatment. The enthusiasm within the neurovascular field regarding this technology and this study is unmistakable. We anticipate enrollment will move quickly, and we think Thunderbolt might reach the U.S. market during the back half of 2023. We've made this point previously, and now physicians who've laid eyes on Thunderbolt concur.

Adam Elsesser

executive
#3

With this technology, the way ischemic stroke is treated could be transformed entirely, improving outcomes for patients while also possibly enabling neuro physicians to safely, effectively, and quickly treat a greater number of ischemic stroke patients. Given that the Thunderbolt trial is now running, it makes sense to take a few minutes to describe what Thunderbolt is and how it functions. Thunderbolt is a microprocessor-controlled advanced software algorithm built into the tubing positioned between the engine pump and the RED catheter. It never enters the patient's body directly. Thunderbolt manages modulating aspiration, which is proprietary to this technology. Within Thunderbolt, two valves are incorporated. One valve links directly to our engine pump from the RED catheter of choice — 62, 68, or 72. A second valve links the RED catheter to a saline bag that is not pressurized. Once clot engagement is detected, the Thunderbolt algorithms manage opening and closing each valve as often as 12 times per second. Such modulated aspiration breaks the friction between the clot and the tip of the catheter. Removing that friction, in our view, will let the RED catheters ingest the clot the vast majority of the time. Contrast this with today's aspiration practice, where ingestion happens only a small percentage of the time, even when larger bore catheters — which are far harder to track to the clot — are used. For that reason, we anticipate Thunderbolt will shift yet another existing paradigm in interventional stroke; our belief is that it will let doctors employ smaller catheters while still gaining the unique advantages of modulating aspiration, achieving faster and more complete clot removal; an added benefit could be a rise in the number of treatable patients, since more distal occlusions could be treated routinely; within our U.S. stroke business, Thunderbolt is plainly the top priority. Beyond that, we also anticipate launching one more RED catheter in the year's second half, which we think will be a highly significant addition to our market-leading portfolio. Additionally, we expect the RED catheter family to launch into the European market in Q3, which will assist us in revitalizing our European neuro business. At this point I'll hand the call to Sandra Lesenfants, President of our Interventional business, so she can share her perspective on our new product pipeline and clinical trial strategy.

Sandra Lesenfants

executive
#4

Good afternoon, and it's a pleasure to be on my first Penumbra earnings call. The bulk of my career has been spent in the interventional space, and what drew me to Penumbra was its distinctive innovation culture along with its dedication to putting patients first. Over the last 18 years, Penumbra's robust innovation culture and its built-in, comprehensive product portfolios have withstood the test of time and proven successful across multiple markets. My belief is that the new product launches, together with supporting clinical data, will usher in another transformative chapter in Penumbra's history. I'm genuinely energized by both of these updates. The patients we're able to reach across our primary interventional markets amount to one of the largest and least-penetrated openings I've seen in my entire career. Over the years, I've had the chance to run some of the biggest and quickest-scaling organizations in interventional medical devices. I can say without any hesitation that the way innovation happens at Penumbra is genuinely on another plane altogether. Here, that innovative culture is one of a kind, it never stops, and above all, it makes a real difference. Adam already walked through the three particular technologies we think have the potential to be genuinely transformative in each of their areas. Thunderbolt for ischemic stroke, Lightning Flash for venous thromboembolism, and Lightning Bolt for peripheral arterial disease. So Thunderbolt, Lightning Flash, Lightning Bolt, plus Lightning 12 and Lightning 7 — every one of those is a proprietary system. Getting these transformational technologies to where they are took many years, and they're shielded by robust intellectual property portfolios. The common thread across this whole lineup is advanced software algorithms run by microprocessors that become part of the system, coordinating how our pump and our catheters behave. When it comes to Lightning Flash, Lightning Bolt, and Thunderbolt, the algorithms built into them are tailored per catheter family — we designed them around whichever approach works best for a given anatomy, whether that's arterial, venous, or neural. Our strategic plan is clear: speed up the shift in mechanical thrombectomy away from traditional Lytics or surgery and toward intelligent aspiration. Our technology stands apart because it's proprietary, straightforward to use, and adaptable. Looking forward, we believe these offerings will enable doctors to provide care to many more individuals—safely, effectively, and with less invasive methods—over the coming months and years. Beyond that, producing fresh scientific data is essential if we're going to hit our goals. On that note, I'm pleased to share that we're entering the strongest period of clinical evidence building this company has ever seen. Alongside the THUNDER trial evaluating Thunderbolt for ischemic stroke, which Adam brought up, there are five more studies either actively recruiting or just finished, spanning stroke, arterial, PE, DVT, and embolization. Beyond that, we're close to finalizing the protocols for a pair of randomized controlled trials—one focused on PE, the other on coronary—and we anticipate kicking those off over the coming quarters. Expect us to share further specifics about both of these key randomized studies before long. When you put it all together—our pipeline of breakthrough technology plus a clinical portfolio that has no equal—we're sitting in an extremely strong spot. That positions us to reach many more patients across the markets we target, to extend our leadership in each of those markets, and to deliver robust growth in the years to come. With that, I'll turn things back to Adam.

Adam Elsesser

executive
#5

Thank you, Sandra. Before handing things to Maggie, I want to share where things stand with our immersive healthcare segment. The notion of applying immersive computing, or virtual reality, to healthcare keeps building steam among medical practitioners, which confirms that putting money into this area was the right call. Interest has risen, and so has usage, for the REAL y-Series we recently brought to market for rehabilitation, which relies on our refreshed hardware along with the many new experiences we introduced during last year's Investor Day. On top of that, something notable happened during this quarter that added further fuel to the interest and momentum behind virtual reality in healthcare. A multi-day summit focused on employing virtual reality to assist our veterans was hosted by the Department of Veterans Affairs. It was an honor to take part in a keynote panel alongside senior VA officials to talk about this vital effort. Their breadth of knowledge and grasp of the subject truly impressed me, as did their readiness to confirm and deliver this technology to serve not just veterans but also the vast number of additional patients who stand to gain. Despite that confidence in the eventual payoff and probable success of our immersive healthcare platform, it's clear the macroeconomic landscape has shifted lately. Given that, our attention is trained on the nearest-term use cases, and that has let us adjust our quarterly spending level in immersive healthcare so it lines up with our commitment to making the company more profitable. Across the coming 12 months, we anticipate cutting more than $10 million in operating expense from this business, even as we keep up the investments we believe will move us toward scaling it over the long haul. I'll pass the call to Maggie now so she can walk through our financial results for the quarter.

Maggie Yuen

executive
#6

Thanks, Adam. Good afternoon, everybody. I'll be going over our Q2 2022 financials today. As in prior quarters, the revenue and gross margin figures discussed on this call are GAAP-based, whereas operating expenses and operating income are non-GAAP. You can find the comparable GAAP figures along with our GAAP-to-non-GAAP reconciliation in the press release we posted. For Q2, which closed on June 30, 2022, total revenues came to $208.3 million — up 13.1% as reported and up 15.3% in constant currency versus Q2 2021. Sales by geography this quarter broke down as 67.9% U.S. and 32.1% international. Within the United States, we posted 10.2% growth, while our international regions delivered a 19.8% revenue increase as reported and 27.2% in constant currency. Turning to revenue by franchise: our vascular business brought in $123.5 million in Q2 2022, rising 22.7% as reported and 24.5% in constant currency against the prior-year period. We achieved double-digit growth in the U.S., EMEA, Asia, and Latin America regions. Our neuro business generated $84.8 million in Q2 2022, up 1.5% as reported and 4.3% in constant currency versus a year earlier. On a sequential basis, neuro revenue rose 4.6% as reported and 5.8% in constant currency, fueled by stronger neuro thrombectomy growth across international regions. Now for gross margin and operating expenses: gross margin for Q2 was essentially unchanged at 64.3%, versus 64.4% in last year's comparable quarter, and it keeps improving quarter over quarter from 62.5% in the prior quarter. The capacity, workforce, and productivity investments we've made over the last 18 months are starting to deliver, both by expanding margin and by helping us work through certain macro labor shortages, inflation, and supply chain headwinds. As we look at the remainder of this year, we anticipate further productivity gains that should offset elevated inflation and supply chain pressures; multiple programs are underway to keep driving gross margin gains going forward. Now to our non-GAAP operating expenses, which exclude this quarter's $1.8 million amortization of acquired intangible assets. Operating expense totaled $132.4 million for the quarter, or 64% of revenue, versus $108.4 million, or 59% of revenue, in the same quarter a year ago. R&D expenses for Q2 2022 came in at $19.6 million, compared with $17.7 million for Q2 2021. SG&A expenses for Q2 2022 were $112.8 million, or 54.2% of revenue, versus $90.6 million for Q2 2021, and $109.1 million against the prior quarter. During Q2, we directed additional investment toward commercial channels and temporary resources to support the migration of our ERP system. In the second quarter of 2022, we posted operating income of $1.6 million, which equals 0.8% of revenue, once you exclude amortization tied to acquired intangible assets. That compares with operating income of $10.3 million during the equivalent period a year earlier. As we move through the back half of 2022, we intend to show greater discipline around discretionary spending, and along with a reduction exceeding $10 million in immersive healthcare operating expenses over the next twelve months, we anticipate ongoing operating margin expansion in sequential quarters. We closed the second quarter with a balance of $204.4 million in cash equivalents and marketable securities. While we did see some delay in receivable collection during the quarter tied to migration of our new ERP system, our team has made strong progress toward restoring a normal collection cycle. At this point, I'd like to hand the call over to Jason so he can walk through our guidance.

Jason Mills

executive
#7

Thanks, Maggie, and good afternoon to all of you. In the second quarter and the first half of 2022, foreign currency translations affected our reported revenue by $4 million and $6 million, respectively. For the full year 2022, we expect the FX impact to come in at roughly $10 million-$15 million. Our guidance of $860 million-$875 million remains unchanged. Because of these FX headwinds, we feel more at ease with expectations toward the lower end of that range; even so, on a constant currency basis, our revenue growth expectation for 2021 comparison stays at 15%-17%. Turning to 2023, Lightning Flash, Lightning Bolt, and Thunderbolt are three paradigm-changing technologies in arterial, venous, and neurothrombectomy, respectively; combined with numerous international growth opportunities and a strong clinical evidence pipeline, these products underscore our confidence in future growth. As a result, we restate our belief that we can speed up our revenue growth in 2023, on both a reported and constant currency basis. I'll now hand the call back to Adam for closing remarks.

Adam Elsesser

executive
#8

Appreciation goes out to Jason, Maggie, Sandra, and the whole team. To wrap up our quarterly earnings discussion, I want to recognize the exceptional efforts put in by everyone at Penumbra during what were extremely difficult conditions. Being part of this group fills me with immense pride. Again and again, they've demonstrated their abilities and determination, joining forces to handle whatever challenges arise. I'd also like to briefly outline the way our Penumbra colleagues operate this business. We're creating solutions capable of benefiting a large patient population, and a great many of those individuals currently lack access to the most sophisticated care available. Uniqueness and transformative impact have always defined our technology. Right now, four major catalysts lie ahead of us — three products along with clinical evidence to back them up — which will enable us to reach a growing number of patients over the coming years. Combined with how carefully we plan and execute, this gives us assurance that we'll achieve robust double-digit growth, raise gross margins substantially, and meaningfully grow operating profitability, all while directing investment at a level commensurate with the sizable opportunities before us. Thank you. We're ready to begin the Q&A session.

Executive

executive
#9

Hello. For today, Robbie has actually got Lilly stepping in to speak instead. We really appreciate you posing that question.

Adam Elsesser

executive
#10

Hey, Lilly.

Executive

executive
#11

Could you put any kind of number on how big the contrast shortage was during the quarter? And how are you weighing that, along with other headwinds such as staffing China, when it comes to your growth across the remainder of the year?

Adam Elsesser

executive
#12

Yeah, that's a terrific question. I sure wish there were a simple method to measure the contrast and what it's doing. There just isn't one. What I'd say is that during the earlier portion of the quarter, this came up far more often. Honestly, as I mentioned during my prepared remarks, at this point we haven't truly been seeing it emerge much as a problem. If we had to identify what's been generating the difficulties and a portion of the headwinds, we believe it's more persistent staffing troubles that have had the larger effect. With that said — and I noted this during my prepared remarks — the final month of, you know, the opening month of this quarter, the most recent 30 days, has. A fairly significant rebound has appeared. Perhaps hospitals are working through their staffing troubles, or perhaps they're discovering how to function in this setting on a more long-term basis — I think it's some mix of the two. Regarding what we've observed during the first month so far, we hold a great deal of optimism.

Jason Mills

executive
#13

Yes, Lillian, let me just build on that a bit. Like Adam mentioned, pinning down an exact figure is really tough; we made an effort to figure it out. It was definitely in the millions of dollars, in our view, but going beyond that in terms of precision is difficult — just attempting to sharpen the picture somewhat.

Executive

executive
#14

Understood, that's quite useful. Thanks. As a quick follow-up, did your U.S. peripheral business expand quarter over quarter? What's your view on that segment for the second half of the year? Many thanks.

Jason Mills

executive
#15

Sorry, just so I heard your question correctly, did you ask U.S. or international?

Executive

executive
#16

U.S. peripheral.

Jason Mills

executive
#17

Right. During the opening six months, our U.S. operations expanded roughly 15%. As Adam pointed out, we definitely experienced shortages in staffing. Compared with the first quarter, macroeconomic difficulties weighed on our American business more heavily in the second. For that segment, we anticipate faster growth across the latter six months. Our expectation is a step up during Q3, followed by an even bigger step up in Q4. When it comes to year-over-year growth for the U.S. in the back half, our view is that it will actually resemble what we saw in the first half — which, as I said, landed in the mid-teens.

Executive

executive
#18

Great. Thank you.

Jason Mills

executive
#19

Thanks.

Adam Elsesser

executive
#20

Thank you.

Executive

executive
#21

Hi, this is Leigh calling in for Larry. Thanks for taking my questions.

Jason Mills

executive
#22

Hi, Leigh.

Executive

executive
#23

Adam. Hi, how are you?

Jason Mills

executive
#24

Well, thank you.

Executive

executive
#25

Alright. Adam, you brought up a recovery in the vascular thrombectomy segment over the last month. Could you share a bit more detail on how that moved during Q2 — did things get worse from April through June, and then was there a significant bounce back in July? Also, any thoughts on what the trend looked like in neuro. I have a follow-up.

Adam Elsesser

executive
#26

Right. Let's kick things off with peripheral and the thrombectomy side of the business. What I was hinting at really relates to the past month — that is, July — when we witnessed a powerful rebound, which likely began somewhat toward the tail end of June too. Part of that, I believe, comes down to hospitals becoming better organized regarding their staffing challenges, and I think they've put in serious effort there. Another piece of it could be competitive share. As I mentioned, we're hearing far more discussions where physicians raise that subject, especially when it comes to DVT. That, I believe, is a larger matter we'll be discussing and tackling moving forward. The mix of those factors, I think, is what's driving the acceleration. Turning to neuro, I can tell you there's growing enthusiasm for Thunderbolt as an increasing number of people get a look at it. A major presentation took place at SNIS featuring a demonstration by a physician involved in the trial; we had plenty of discussion around that, with people approaching us throughout the week to talk about it. I sense genuine excitement there. Naturally, the RED catheters play a role in that current success.

Jason Mills

executive
#27

Yes, and I’ll build on what Leigh said. When we examine the core fundamentals of our peripheral thrombectomy business closely, they remain quite solid and were solid throughout Q2. In July, we observed ongoing strengthening from what was already a robust underlying base. Broadly, we anticipate that pattern will persist during the latter half of this year.

Executive

executive
#28

Okay, thank you. Now regarding gross margin, could you say whether we ought to anticipate a step-up from one quarter to the next in the back half? Any remarks on the main factors that would bring us to a gross margin of 70%+ over the coming years? Thanks.

Maggie Yuen

executive
#29

Appreciate the question. We're really thrilled about the momentum we're seeing around productivity gains, particularly at our Roseville site, along with the manufacturing transfer work. Much of the productivity improvement showing up this quarter comes from those initiatives. Looking sequentially, there's still some low-hanging fruit remaining, plus plenty of other efforts we're pursuing. We'll keep seeing gains, and we'll keep steering through FX, inflation, and supply chain challenges. Over the longer term, we'll certainly keep pushing improvement forward, with new product launches driving a favorable mix. Several of the larger programs we've put in place will set us on the right course toward that 70%+ gross margin objective.

Jason Mills

executive
#30

Thanks, Leigh.

Executive

executive
#31

Hey, everyone.

Jason Mills

executive
#32

Hello.

Executive

executive
#33

Hey, everyone. It's John on for Bill tonight.

Jason Mills

executive
#34

How are you doing?

Executive

executive
#35

Appreciate you taking my questions. So, you just posted a really strong OUS quarter, and I'd like to dig into that a bit further. Is that largely driven by the European rollout of the Lightning 7 and 12? And how should we frame what OUS adds in the back half of the year toward the total revenue goals?

Jason Mills

executive
#36

Appreciate that, John. That's a solid one. During the quarter, expansion and the added contribution came from many parts of our overseas operation. For sure, the Lightning rollouts across Europe and EMEA as a whole played a part in that. We're eager for the RED introductions in that very same area during this quarter. We additionally recorded wide-ranging gains throughout Asia Pacific, China included, and anticipate ongoing expansion in that market along with Japan. Naturally, we noted the possibility that our vascular thrombectomy offerings could arrive there sooner than we had anticipated. On the international front, the direction appears to be a sturdy one.

Executive

executive
#37

Alright, thank you for that. Now, regarding this call, clearly you've pointed out all the difficulties in the macro backdrop as well as FX. So, how confident are you about still reaching that goal of $1 billion in sales for 2023? Given everything happening at present, do you believe it's still achievable?

Jason Mills

executive
#38

Yes.

Executive

executive
#39

Great. Thank you.

Jason Mills

executive
#40

Thanks, John. Thank you.

Pito Chickering

analyst
#41

Hey there, good afternoon. Appreciate you taking my questions. I've got a few follow-ups regarding the revenue lines. Was there any noticeable variation in demand when comparing urban hospitals to the somewhat smaller ones, specifically around staffing? Also, could you give some detail on the growth trajectory for vascular and neuro in the US compared to international?

Jason Mills

executive
#42

We'll take the first one, Pito Chickering — glad to have you on the call. No clear distinction stood out to us. From what customers have told us, whether those are smaller facilities or bigger academic centers, both are facing identical macroeconomic pressures, whether that's staffing challenges in nursing or tech, or something else. That held true as well when contrast availability was more problematic earlier in the quarter, broadly speaking. As for your second question regarding U.S. versus international, we clearly aren't providing that level of detail on the split between domestic and overseas within our businesses. That said, the key takeaway worth emphasizing is the fundamental strength underlying our thrombectomy businesses. I believe your question was about thrombectomy businesses; across neuro, honestly, and peripheral vascular, both are performing very strongly. Growth in neurothrombectomy is clearly slower at present, but the momentum behind Thunderbolt. We're quite enthusiastic about.

Pito Chickering

analyst
#43

All right, that's reasonable. One more thing from me about gross margins, and I want to focus on the interventional area. How much do those differ from what your pure play competitor reports? Could you give any specifics about the cost pressures you're observing there, and that would take in Immersive Health as well, plus how are we meant to weigh those cost pressures against the savings that come from the Roseville manufacturing facility once it's up and running?

Maggie Yuen

executive
#44

Yes, I appreciate that. Regarding thrombectomy margin, I'd say the main gap when you compare us to rivals comes down to pricing; broadly speaking, across our company, thrombectomy carries a stronger margin than what we get from embolization. Looking ahead, we expect productivity to keep getting better, something we've been pursuing over the past 12 to 18 months, and that should counter the macro headwinds we anticipate during the second half.

Pito Chickering

analyst
#45

Great. Thanks so much.

Jason Mills

executive
#46

Thank you.

Adam Elsesser

executive
#47

Thank you, Pito.

David Rescott

analyst
#48

Hello, everyone. Appreciate you answering our questions. Hi, Jason. Adam, to begin with the U.S. peripheral thrombectomy business — clearly, across the last several years you managed to build that market from nothing, and notably, you had a strong quarter despite the headwinds in that segment. I'm just curious whether now, or at some later point, we might expect a bit more detail, you know, on the separate pieces inside that business — specifically arterial or coronary PE DVT — regarding how each has been developing compared with the others and compared with the broader market overall.

Jason Mills

executive
#49

Yes, that's a fair question. I'll begin, and Jason can chime in. When it comes to arterial versus the bigger venous side, there is a way to describe it somewhat. My sense is that splitting that out now would be premature, simply because of how we think about and operate those businesses, since we're attempting to build every one of them simultaneously. That should prove more useful once the business matures. Down the road, though, when it comes to DVT and PE, it's going to be difficult, because the products are going to be identical, and figuring out that answer becomes much harder; obviously, things would be different if our products were distinct. We'll share whatever color commentary we can regarding the success we're achieving. I touched on that during this call, especially concerning certain competitive wins. We'll keep doing that to the best of our ability.

Adam Elsesser

executive
#50

Right. David, to build on that point, when you examine the different market segments, or the patient groups that are specific to each of those areas. Consider what we mentioned during the prepared remarks regarding the technologies we're introducing that are tailored to each of those anatomies. Combine that with the previous point, the fairly low penetration in terms of where we stand in reaching or assisting patients in those markets, that's the reason we stated during the call that we believe we're on the verge of entering the strongest period in Penumbra's history. With the microprocessor-controlled algorithms built into each of these technologies, and we announced a Lightning Flash for venous thrombolysis, as an example, it enables us to provide the most sophisticated therapy that the industry has ever witnessed in thrombectomy, in venous thrombolysis. The same applies to a Lightning Bolt in arterial, CAT RX in coronary; we feel really positive about that and backing it with clinical evidence, genuine, clinical evidence. We feel very good about where we're headed.

David Rescott

analyst
#51

All right, thank you. I suppose regarding what you'll spend during this year, plus what will be spent across the coming couple of years, what's your thinking there? In earlier periods, I recall you described an emphasis on growth rather than — or measured against — margin expansion. As you consider outlays spanning the next several years, where would the biggest portion, or the greatest dollars, be directed? Would that be Thunderbolt, the VR opportunity, or simply growing neurovascular and peripheral? I'd really appreciate some sense of the spend's longer-term outlook. Thanks.

Maggie Yuen

executive
#52

Fine. I'll take that one. Appreciate the question. From the perspective of total operating expense, particularly when I look at the prior 12 months, our investment has been fairly even across product development, the sales force, international, and overall infrastructure too. I believe we now sit at a solid level from which to begin scaling those opportunities, while also becoming somewhat more disciplined around certain discretionary items. Like Adam said before, that holds even in some cost savings areas — provided we aren't doing so at the expense of developing the pipeline.

Adam Elsesser

executive
#53

Thank you, David.

Mike Matson

analyst
#54

Sure, I appreciate you fielding my questions.

Adam Elsesser

executive
#55

Hi there, Mike.

Mike Matson

analyst
#56

I'd like to bring up Lightning Flash and Bolt. With both of those on the market, it seems like their capabilities differ somewhat. I assume you also still have the earlier, original Lightning, right? So how will pricing work across the different tiers? Will it be some sort of tiered structure? And where do you expect Flash versus Bolt to be adopted? Are they aimed at separate kinds of procedures, or something along those lines?

Adam Elsesser

executive
#57

Yeah, that's a wonderful question. During the prepared remarks I mentioned that Lightning Bolt is mainly built for the arterial side, while the venous side is where Lightning Flash is mainly used. That's basically the core distinction. As everyone knows, arteries and veins differ enormously. Their function is not the same. The way you handle them has to differ. On top of that, their sizes aren't the same either. With that said, regarding the pricing question and everything related, once we've gotten the products cleared by the FDA and into the market, we'll take up how we price them and how we approach that. But I can share this: having spent nearly 20 years now involved in stroke, and having observed how innovation has unfolded in stroke, plus everything our field and even our company once did to extract clot, and where we're about to stand with Thunderbolt, it creates a comparable feeling on the peripheral side as well — that we can actually reach a point where we aren't doing the sorts of things we practically had to do previously to pull clot out, and introducing long-term risk to vessel walls and so forth; this technology, across all of them, carries a great deal of meaning for the people here. It's the sort of thing we pursue when we truly complete the innovation arc we began in working to remove clot from the body. There's enormous passion and a tremendous amount of remarkable effort invested in these; once they're on the market, we'll handle pricing. Exciting times. Thanks for the question, Mike.

Mike Matson

analyst
#58

Yeah. And as a quick follow-up on the REAL System—since you're aiming it at what you described as immediate use cases—could you describe those? What does your pricing structure look like at present? I don't need specific figures, but previously you mentioned something like a rental approach, while more lately it sounds like you've discussed something closer to a capital sale approach. Any detail on that would be useful. Thanks.

Adam Elsesser

executive
#59

Yeah. That's a terrific question. A moment will come, and a setting will come, for discussing those models. I've said plainly that we'll make every effort to keep everyone informed about the models while we work out the appropriate approach for the field. What I believe we should concentrate on at this moment is this: where are we able to help? Where do people require this product? I just have to—please allow me one moment, if you will. I brought up the meeting that the VA organized. That was a remarkable occasion. I felt honored to receive an invitation, and I was truly astonished that the Veterans Administration was putting this on. A great many attendees were present, some physically and some remotely. They discussed—and they also had quite a few other parties, vendors and such. It was a fairly wide-ranging gathering. Being able to exchange views and discuss how to determine not merely which applications, because to some extent they already understand that, but how do you bring this into practice? What does the workflow resemble, within a healthcare system? Clearly, VA is the biggest healthcare system in the U.S. I have to say, then hearing a panel following our panel, consisting of veterans, and having those veterans recount their own experiences—having used VR and what effect that had for them and how it started not just therapy with VR, but therapy through other means as well—is. You know, there's an enormous opportunity, naturally, to assist everybody, but if we're able to assist our veterans, we will have accomplished something worthwhile collectively, and I believe it spurred us to be efficient in how we direct our attention and direct our spending so that we can be genuinely, genuinely useful to these individuals; so that is the top priority at present, and we are quite dedicated to it. Thank you.

Mike Matson

analyst
#60

Okay. Got it. Thank you.

Adam Elsesser

executive
#61

Thanks, Mike.

Analyst

analyst
#62

Hi there, good afternoon. I'm Avian, calling in on behalf of Shagun. Appreciate you taking the question. I wanted to build on what we discussed regarding immersive healthcare and our virtual reality platform — it's encouraging that feedback has been so positive, but which metrics are you planning to report for REAL over the coming quarters? Could you also walk us through how reimbursement should be viewed while the platform is being rolled out? And what makes you confident that REAL will become your biggest business within the next 5 to 6 years?

Adam Elsesser

executive
#63

Like I've told you, the moment we're in a position to do so, with the level of certainty and specificity that all of you are owed, that information will be shared. At this point — and this is something I picked up quite a while back, when the company was just getting off the ground — let me remind everybody that when we first began contemplating a stroke product, reimbursement simply didn't exist. Nobody had any interest in treating stroke, and there was no infrastructure in place for it. Not one of those things stopped us. We simply charged ahead, because we were focused on what mattered most: there were patients suffering strokes, and we believed we could contribute something meaningful. The situation here is identical. That's what made the summit at the VA so encouraging, especially seeing the patients who are currently gaining benefit from immersive therapy. We will get that information to you as quickly as we can, and as responsibly as we can. What fuels our confidence is that people are already experiencing benefits, and from here we simply need to work out how to deliver it and how to incorporate it into the workflow of complex healthcare systems. That, as you know, is not simple. It's difficult work, and it carries some uncertainty. It's no different from anything else we've undertaken that involved uncertainty, and I believe we are extremely well positioned, and we have the mentality not to merely, you know, trail behind what others are doing, but to venture into new territory with the aim of helping people — our veterans especially.

Jason Mills

executive
#64

Yes. Jason here, chiming in on that. When it comes to the guidance we provided, both the numbers-based outlook for this year and, to a degree, the qualitative outlook we gave for 2023, keep in mind that all of it covers only our interventional business. I simply wanted that point to be unambiguous. As we'll discuss further down the road, the financial model and business model behind immersive healthcare is, and has the potential to be, a really strong, lucrative one for this company. To be sure, it differs from other standard medical device models, yet even so, it's opportunistic when you consider the opportunity, not just on the top line, but also margins and profitability across the longer term. That's all I wanted to add. Thanks.

Analyst

analyst
#65

Appreciate it.

Brandon Vazquez

analyst
#66

Hello, all. Thanks for taking my question.

Adam Elsesser

executive
#67

Hello, Brandon.

Brandon Vazquez

analyst
#68

I'd like to ask — hey, everyone. Regarding the vascular segment, you mentioned staffing shortages a bit and the way that affected the quarter. That remark struck me as somewhat curious, since it appeared that during COVID, one of the best things about the vascular segment was that you folks were sort of the answer to the issue, correct? Hospitals were overwhelmed, and you could step in with Lightning — or Indigo, as it was called before — and get patients out faster and more safely than before. I figured that might be a pattern that could persist with fewer staff. They might still have to depend on a company like yours. Am I overlooking something there, and could you perhaps explain why that dynamic wouldn't have shown up in Q2 and why staffing shortages hit more sharply this quarter?

Jason Mills

executive
#69

Yeah, definitely. That's an excellent question, and thank you for the chance to clear that up. The staffing shortages we're facing — honestly, those affecting others across not just endovascular med tech, but also beyond, in wider med tech areas — are truly procedural staffing shortages. If you lack the staff to perform the procedure, or to perform as many procedures as you'd otherwise want to, you simply can't perform them. What I believe you're alluding to is that there certainly was pressure on the healthcare system and on healthcare professionals at large during COVID to keep these patients out of the ICU. Without a doubt, that benefited the thrombectomy business in general, since we can keep patients out of the ICU — or at minimum, cut down their time there. I think these are two separate challenges you're bringing up, but they're not alike.

Brandon Vazquez

analyst
#70

Alright. If I've got this wrong, please set me straight, but from what I gathered in the prepared remarks, the vascular business saw somewhat fewer new accounts brought on during the quarter. Things seemed to pick back up by the time you left the quarter or entered Q3. Could you explain what the ramp timeline looks like for some of those new accounts? Part of what I'm getting at is whether that small stretch of fewer or lower account openings ends up producing a sort of growth pocket over the coming one or two quarters, once you're back on the offensive, bringing on new accounts and ramping them.

Jason Mills

executive
#71

Yes, that's a wonderful question. I simply wanted to tack something onto that. As Adam's broader response, and just to remind everyone, the first quarter—I think we made a comment about this—was the best quarter we'd recorded, ever since the Lightning 12 launch, when it came to new account additions, within the United States. So in a sense there's a bit of, you know, those being consolidated. Still, I wanted to flag that. Adam, perhaps you could pick up the rest of that response.

Adam Elsesser

executive
#72

Yeah, I think regarding account openings and everything, the thing I wanted to ensure came across clearly is that what happened this quarter resulted from utilization of our product, not from stockpiling of new accounts. That was really the key takeaway; we focused heavily on the customers. Like I mentioned, there was some curiosity among a number of them—people who were just getting going with our product and already were doing mechanical thrombectomy—to give ours a try; that, you know, obviously demanded attention as they kind of progressed to the sort of, you know, the next thing that works. I want to be clear, you know, about precisely what I said concerning new accounts versus stocking.

Jason Mills

executive
#73

Right, Brandon, that essentially sums up how the company approaches things. Take the new accounts opened during Q1 — that was utilization too. I just want to make the point clear regarding what we normally do.

Brandon Vazquez

analyst
#74

Great. Thanks very much.

Adam Elsesser

executive
#75

Thanks.

Pito Chickering

analyst
#76

Hi, everyone. I appreciate you letting me jump back in with one more question. Of the stroke reperfusion work you're doing right now, what portion involves RED as opposed to JET 7? When physicians reorder, has the pattern with RED differed from what it used to be? Where do you believe your market share stands now compared with 12 months ago?

Adam Elsesser

executive
#77

That's quite a few questions at once. Let me begin. Off the top of my head, I can't give you a figure splitting RED and the other one. Within the U.S., my sense would be-

Jason Mills

executive
#78

It's the majority.

Adam Elsesser

executive
#79

Yeah.

Jason Mills

executive
#80

That accounts for more than half.

Adam Elsesser

executive
#81

Overwhelmingly so. An exact figure isn’t something I can provide, yet what’s being used right now has overwhelmingly moved over to the RED series. What we observe is a wide span: 62%, 68%, and 72%.

Jason Mills

executive
#82

Absolutely.

Adam Elsesser

executive
#83

Yeah, plenty of folks gravitate toward those options, depending on what they prefer and such. That accounts for the bulk of the switching among the customers we have now. My sense is a recovery has taken hold, clearly, as the figures we posted suggest, and in share as well. I believe that trend keeps going, exactly as I stated plainly after SNIS, and then during July, with plenty of enthusiasm carrying forward thanks to Thunderbolt and, naturally, Thunderbolt's compatibility with RED catheters and similar items. At this moment, I'd say our position looks quite solid. I'm eager to begin discussing Thunderbolt and, you know, demonstrating it in action for all of you.

Pito Chickering

analyst
#84

Great. Thanks so much.

Adam Elsesser

executive
#85

Thanks. Thank you.

Jee Hamlyn-Harris

executive
#86

Appreciate it, operator. Speaking for the management team here, thanks once more for being with us today and for the interest you've shown in Penumbra; we're glad to bring you up to speed on our call for the third quarter.

Operator

operator
#87

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.